Indigenous CAR-T cell therapy now available for commercial use: ‘first’ patient declared free of cancer
- The commercial use of CAR-T cell therapy has shown significant advancements have been observed in cancer treatment.
About CAR-T Cell Therapy
- The pioneering treatment that genetically reprograms a patient’s immune system to fight cancer
- The therapy is showcasing promising results post-treatment.
- It is a revolutionary therapy that modifies immune cells, specifically T-cells, into potent cancer fighters known as CAR-T cells.
- The therapy involves collecting and genetically modifying the patient's T-cells to express chimeric antigen receptors (CARs) specific to cancer cells.
- These modified cells are then infused back into the patient to target and attack cancer cells
- This offers a targeted immunotherapy approach.
Success of Therapy
- CAR-T cell therapy highlights its efficacy in treating B-cell cancers, particularly acute lymphoblastic leukaemia.
- Initial findings suggest promising survival rates and lower remission rates.
- This indicates the potential to reduce cancer-related mortality and revolutionise cancer treatment.
Indigenously Developed Therapy
- NexCAR19(the title of therapy)is developed collaboratively by ImmunoACT, IIT Bombay, and Tata Memorial Hospital.
- ImmunoACT’s is the first CAR-T cell therapy to get CDSCO approval.
- The therapy received approval from the Central Drugs Standard Control Organisation (CDSCO) in October 2023,
- The development of the therapy is marking a significant milestone in cancer treatment in India.
Prelims Takeaway
- CAR-T Cell Therapy
- Chimeric Antigen Receptors